Derek Gumm is a transactional tax associate in the San Francisco office of Latham & Watkins.

Mr. Gumm advises US and non-US corporations, private equity funds, and investment banks in a variety of US and international contexts and specifically on federal tax issues related to mergers, acquisitions, divestitures, financings, restructurings, and post-merger integration.

Mr. Gumm received his JD from the Northwestern University School of Law, where he served as an editor of the Northwestern University Law Review. Prior to joining Latham, Mr. Gumm was an associate at another leading international law firm. 

Mr. Gumm’s experience includes advising:

  • IDEAYA Biosciences, Inc. in its US$80 follow-on public offering
  • Amplitude in its US$1.8 billion direct listing
  • Clarify Health in its acquisition of Embedded Healthcare
  • CooperCompanies in its acquisition of Cook Medical’s Reproductive Health business
  • Evernote in its acquisition by Bending Spoons
  • Extensiv in connection with a US$80 million senior secured loan from Runway Growth Capital
  • Francisco Partners on financing in connection with SatixFy’s US$813 million SPAC transaction
  • Headspace in its merger with Ginger to create Headspace Health
  • Imago BioSciences in its US$1.4 billion acquisition by Merck
  • John Deere in its US$250 million acquisition of Bear Flag Robotics
  • Khosla Ventures Acquisition Co. II in its merger with Nextdoor to make Nextdoor a publicly listed company
  • Laminar, Inc. in its US$400 million acquisition by Johnson & Johnson Medtech
  • Pionyr Immunotherapeutics in its US$43 million acquisition by Ikena Oncology 
  • Prysm Collective in its acquisition by NEP Group to create NEP Virtual Studios
  • Revolution Medicines in its US$230 million and US$300 million follow-on public offerings
  • Rhythm Pharmaceuticals, Inc. in a global licensing agreement with LG Chem
  • Seres Therapeutics in its license agreement with Nestlé Health Science to jointly commercialize SER-109, Seres’ investigational oral microbiome therapeutic for recurrent Clostridium difficile infection (CDI), in the United States and Canada
  • ShapeTX with respect to its collaboration with Otsuka to develop novel AAV gene therapies for ocular diseases
  • Staked Securely, Inc. in its sale to Payward (dba Kraken)
  • Starry Group Holdings in its US$290 million chapter 11 debt restructuring
  • Thumbtack in its US$275 million investment
  • TLM in its acquisition by Endava
  • The underwriters in Chinook Therapeutic’s US$105 million follow-on public offering
  • The underwriters in HashiCorp’s US$1.2 billion initial public offering
  • The underwriters in Twist Biosciences’ US$250 million upsized public offering
  • Vaxcyte in its US$500 million follow-on public offering
  • Virgin Orbit in its chapter 11 restructuring 

Bar Qualification

  • California

Education

  • JD, Northwestern University School of Law, 2017
    cum laude
  • MA in Philosophy, Colorado State University, 2013
  • BA in Philosophy, Grinnell College, 2011

Languages Spoken

  • English

Practices